BACKGROUND: Acute myeloid leukemia (AML) cases with t(8;21) or inv(16) have a favorable outcome, but the associated prognoses are heterogeneous and complicated by additional molecular aberrations. PATIENTS AND METHODS: Between January 2000 to December 2010, 67 patients were diagnosed with t(8;21) or inv(16) AML. We collected cytogenetic variables and analyzed treatment outcomes. RESULTS: Among 67 patients, 51 (7.8%) had t(8;21) AML and 16 (2.4%) had inv(16) AML. Thrombocytopenia, and a high percentage of blasts in the peripheral blood and bone marrow were associated with poor overall survival. Twenty-five (49.0%) patients with t(8;21) had an additional chromosomal abnormality, while only six (37.5%) patients with inv(16) AML had a secondary chromosomal abnormality. The most common chromosomal abnormalities were deletion of the Y or X sex chromosomes. CONCLUSION: Deletion of the Y chromosome may be a favorable prognostic factor in patients with core binding factor-positive AML.
BACKGROUND:Acute myeloid leukemia (AML) cases with t(8;21) or inv(16) have a favorable outcome, but the associated prognoses are heterogeneous and complicated by additional molecular aberrations. PATIENTS AND METHODS: Between January 2000 to December 2010, 67 patients were diagnosed with t(8;21) or inv(16) AML. We collected cytogenetic variables and analyzed treatment outcomes. RESULTS: Among 67 patients, 51 (7.8%) had t(8;21) AML and 16 (2.4%) had inv(16) AML. Thrombocytopenia, and a high percentage of blasts in the peripheral blood and bone marrow were associated with poor overall survival. Twenty-five (49.0%) patients with t(8;21) had an additional chromosomal abnormality, while only six (37.5%) patients with inv(16) AML had a secondary chromosomal abnormality. The most common chromosomal abnormalities were deletion of the Y or X sex chromosomes. CONCLUSION: Deletion of the Y chromosome may be a favorable prognostic factor in patients with core binding factor-positive AML.
Authors: Soheil Meshinchi; Jessica A Pollard; Katherine Tarlock; Todd A Alonzo; Yi-Cheng Wang; Robert B Gerbing; Rhonda Ries; Michael R Loken; Laura Pardo; Tiffany Hylkema; Jason Joaquin; Leela Sarukkai; Susana C Raimondi; Betsy Hirsch; Lillian Sung; Richard Aplenc; Irwin Bernstein; Alan S Gamis Journal: Clin Cancer Res Date: 2019-06-10 Impact factor: 12.531
Authors: Kim Klein; Gertjan Kaspers; Christine J Harrison; H Berna Beverloo; Ardine Reedijk; Mathilda Bongers; Jacqueline Cloos; Andrea Pession; Dirk Reinhardt; Martin Zimmerman; Ursula Creutzig; Michael Dworzak; Todd Alonzo; Donna Johnston; Betsy Hirsch; Michal Zapotocky; Barbara De Moerloose; Alcira Fynn; Vincent Lee; Takashi Taga; Akio Tawa; Anne Auvrignon; Bernward Zeller; Erik Forestier; Carmen Salgado; Walentyna Balwierz; Alexander Popa; Jeffrey Rubnitz; Susana Raimondi; Brenda Gibson Journal: J Clin Oncol Date: 2015-11-16 Impact factor: 44.544
Authors: A D Kelly; H Kroeger; J Yamazaki; R Taby; F Neumann; S Yu; J T Lee; B Patel; Y Li; R He; S Liang; Y Lu; M Cesaroni; S A Pierce; S M Kornblau; C E Bueso-Ramos; F Ravandi; H M Kantarjian; J Jelinek; J-Pj Issa Journal: Leukemia Date: 2017-01-11 Impact factor: 12.883